Holen Sie sich die Stockscreener-App
0.5167
5.43%
0.0266
Schlusskurs vom Vortag:
$0.4901
Offen:
$0.529
24-Stunden-Volumen:
112.20K
Relative Volume:
0.03
Marktkapitalisierung:
$14.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.23M
KGV:
-3.4608
EPS:
-0.1493
Netto-Cashflow:
$-10.48M
1W Leistung:
+5.88%
1M Leistung:
+32.49%
6M Leistung:
-33.76%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.4976
$0.55
1-Wochen-Bereich:
$0.436
$0.55
52-Wochen-Spanne:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Firmenname
Curanex Pharmaceuticals Inc
Sektor
Branche
Telefon
718-673-6078
Adresse
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.5167 | 13.89M | 0 | -4.23M | -10.48M | -0.1493 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Curanex Pharmaceuticals Inc Aktie (CURX) Neueste Nachrichten
Curanex Pharmaceuticals Highlights Patient Case Supporting Phyto-N's Potential in Cancer Cachexia Treatment - Quiver Quantitative
One cancer patient kept working 2+ years in Curanex Phyto-N case - Stock Titan
EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy - Benzinga
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases - MSN
Curanex Pharmaceuticals Inc (CURX) stock price, news, quote and history - Yahoo Finance UK
Curanex Pharmaceuticals Inc (CURX) latest stock news and headlines - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Curanex adds cancer cachexia to drug development pipeline - Investing.com
Curanex Pharmaceuticals Expands Drug Development Pipeline - TradingView
Curanex Adds Cancer Cachexia to Core Drug Pipeline - TipRanks
Curanex (Nasdaq: CURX) targets cancer cachexia in expanded pipeline - Stock Titan
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company - The Manila Times
Curanex adds cancer cachexia to drug development pipeline By Investing.com - Investing.com UK
No U.S.-approved treatment exists for cancer cachexia. Curanex adds it - Stock Titan
Curanex Pharmaceuticals and Phyto-N: Botanical Drug Development for Inflammatory Diseases, COVID-19, Diabetes, NAFLD, and Gout 33 - Minichart
Curanex Advances Phyto-N Toward IND Submission in 2026 Annual Report - National Today
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission - Bitget
CURX: IPO proceeds fund R&D for Phyto-N; no revenue, $4.2M net loss, and internal control weaknesses - TradingView
Curanex Pharmaceuticals Inc Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Curanex Pharmaceuticals (NASDAQ: CURX) outlines multi-disease Phyto-N drug strategy - Stock Titan
Curanex Pharmaceuticals Advances Key Milestones in Manufacturing, Toxicology, and Regulatory Strategy for Phyto-N Development - Quiver Quantitative
Ulcerative colitis drug candidate stays on track for late-2026 filing - Stock Titan
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours - MSN
Stock List: Research Stocks from Around the World - GuruFocus
CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - chartmill.com
CURX Should I Buy - Intellectia AI
Nasdaq tumbles over 350 points; US initial jobless claims increase - MSN
Curanex Pharmaceuticals IncTargets Ind Submission For Phyto-N In Q4 2026 - TradingView
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission - Yahoo Finance
Curanex adds two pharmaceutical veterans to advisory board By Investing.com - Investing.com Nigeria
Curanex adds two advisors to scientific board ahead of IND filing By Investing.com - Investing.com India
Curanex adds two advisors to scientific board ahead of IND filing - Investing.com Australia
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers - Bitget
TB and COVID scientists join Curanex board to steer 2026 trial plans - Stock Titan
Curanex adds two pharmaceutical veterans to advisory board - Investing.com India
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board - marketscreener.com
Veteran drug creators with HIV, HCV medicines join Curanex - Stock Titan
Curanex Formalizes Long-Term Executive Employment and Compensation Agreements - TipRanks
Curanex Pharmaceuticals Inc Enters into Executive Employment Agreement with Jun Liu as President and Chairman of the Board, Effective March 1, 2026 - marketscreener.com
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Curanex Forms World Class Scientific Advisory Board - Bitget
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Stocks in the News: ALBT, NDRA, CURX, HCTIAI, Clinical Milestones Drive Market Surges - marketscreener.com
Market Movers | Winners: IXHL, ALBT, RXT | Losers: THRY, EOSE, ERII - Trefis
Finanzdaten der Curanex Pharmaceuticals Inc-Aktie (CURX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):